Skip to main content

Table 2 Characteristics of patients of individual studies included in the qualitative systemic review

From: Contralateral risk-reducing local therapy in breast cancer patients with BRCA1/2 mutations: systemic review and meta-analysis

First author Year BRCA1/BRCA2 No. with PT
(BRCA1/2)
No. with
no PT
(BRCA1/2)
Mean age
at UBC
diagnosis
(PT/NPT)
Mean
age at
PT
Stage Interval
van Sprundel [17] 2005 115/43 79(60/19) 69(55/14) 38.0/39.4 41.9 I-III 4.0 ± 0.5
Kiely [11] 2009 161/127 154 864 46.7 NR I-III NR
Evans [10] 2013 NR 105(51/54) 593 (NR) 40.3/44.5 44 I-III 1.1(0.0-13.3)
Evans [10]
(matched)a
2013 102/108 105(51/54) 105(51/54) 40.3/41.5 44 I-III 1.1(0.0-13.3)
Metcalfe [18] 2014 226/158 181(103/76) 209(123/82) 43.6/41.3 NR I-II 2.3
Heemskerk-
Gerritsen [19]
2015 454/129 242(193/49) 341(261/80) 38/42 NR I-III 2.0(0-20.2)
Fachinetti [35] 2019 70/58b NR NR 44 NR NR NR
Evron [36] 2019 81/81 54/29 59/22 NR 50.4 I-III NR
  1. Interval: Time between primary BC diagnosis and prophylactic treatment
  2. PT prophylactic treatment, UBC unilateral breast cancer
  3. a105 patients of the surveillence group were matched for the contralateral prophylactic mastectomy group and formed a prospective cohort
  4. bNot all patient received surgery